Overview

Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)

Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
In this postmarketing study, the safety of Nonafact® (human coagulation factor IX) is evaluated in previous treated and untreated patients with severe, moderate or mild haemophilia B.
Phase:
Phase 4
Details
Lead Sponsor:
Sanquin
Sanquin Plasma Products BV